Trial · NCT03693833
CBD Treatment in Hand Osteoarthritis and Psoriatic Arthritis.
NCT03693833, Phase 2, Completed, Aalborg University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CBD Treatment in Hand Osteoarthritis and Psoriatic Arthritis. Trials, record NCT03693833. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03693833
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CBD Treatment in Hand Osteoarthritis and Psoriatic Arthritis.
- NCT number
- NCT03693833
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 136 participants, actual
- Lead sponsor
- Aalborg University Hospital
- Conditions
- Psoriatic Arthritis, Hand Osteoarthritis
- Interventions
- Cannabidiol, Placebo Oral Tablet
- First posted
- 2018-10-03
- Last updated
- 2021-07-07
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | VAS pain during the last 24 hours | Change from baseline to 12 weeks | Measure with a 100mm Visual Analogue Scale (VAS) with higher values indicating more pain. |
| Other | Patients experiencing adverse events | 24 weeks | Percentage of patients experiencing adverse events in placebo and intervention group |
| Other | Characterization of serious adverse events | 24 weeks | Description of which serious adverse events where experience in each group |
| Other | Difference in VAS-pain at the 24-week follow-up visit between the intervention and placebo group. | at 24week followup | Measure with a 100mm Visual Analogue Scale (VAS) with higher values indicating more pain. |
| Other | Correlation between baseline quantitative sensory testing (QST) and treatment effect after 12 weeks. | at 12week visit | QST measurements will include pain detection threshold, pain tolerance threshold, temporal summation and conditioned pain modulation |
| Other | Correlation between baseline psychosocial parameters, patient reported outcomes (PROMs) and treatment effect | at 12 week visit | patient reported outcome includes: Expected effect of treatment is measured using the Stanford expectations scale. Pain catastrophizing thoughts are measured using the Pain catastrophizing scale. Presence of widespread pain is evaluated using the Widespread Pain Index and the Symptom Severity Scale. Sleep quality is evaluated using the Pittsburgh Sleep Quality Index. Presence of anxiety and depression is measured using the Hospital Anxiety and Depression Scale. Furthermore, pain phenotype will be quantified using the Pain Detect Questionnaire and Short Form McGill questionnaire. Quality of life is quantified using the Short form 36 and disability using the Health Assessment Questionnaire Disability Index and Functional index of hand osteoarthritis. |
| Other | 5. Difference in changes of the psychosocial parameters and PROMs between the intervention and control group after 12 weeks of treatment | at 12 week visit | patient reported outcome includes: Expected effect of treatment is measured using the Stanford expectations scale. Pain catastrophizing thoughts are measured using the Pain catastrophizing scale. Presence of widespread pain is evaluated using the Widespread Pain Index and the Symptom Severity Scale. Sleep quality is evaluated using the Pittsburgh Sleep Quality Index. Presence of anxiety and depression is measured using the Hospital Anxiety and Depression Scale. Furthermore, pain phenotype will be quantified using the Pain Detect Questionnaire and Short Form McGill questionnaire. Quality of life is quantified using the Short form 36 and disability using the Health Assessment Questionnaire Disability Index and Functional index of hand osteoarthritis. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03693833
GET https://conductscience.org/api/trials/v1/NCT03693833/registered